116 related articles for article (PubMed ID: 12543792)
1. Antitumor activity of the 16-kDa prolactin fragment in prostate cancer.
Kim J; Luo W; Chen DT; Earley K; Tunstead J; Yu-Lee LY; Lin SH
Cancer Res; 2003 Jan; 63(2):386-93. PubMed ID: 12543792
[TBL] [Abstract][Full Text] [Related]
2. A molecular mimic of phosphorylated prolactin markedly reduced tumor incidence and size when DU145 human prostate cancer cells were grown in nude mice.
Xu X; Kreye E; Kuo CB; Walker AM
Cancer Res; 2001 Aug; 61(16):6098-104. PubMed ID: 11507059
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific expression of the diphtheria toxin A chain (DT-A): studies of inducibility and specificity of expression of prostate-specific antigen promoter-driven DT-A adenoviral-mediated gene transfer.
Li Y; McCadden J; Ferrer F; Kruszewski M; Carducci M; Simons J; Rodriguez R
Cancer Res; 2002 May; 62(9):2576-82. PubMed ID: 11980652
[TBL] [Abstract][Full Text] [Related]
4. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
Igawa T; Lin FF; Rao P; Lin MF
Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated interferon-beta gene transfer inhibits angiogenesis in and progression of orthotopic tumors of human prostate cancer cells in nude mice.
Lee J; Wang A; Hu Q; Lu S; Dong Z
Int J Oncol; 2006 Dec; 29(6):1405-12. PubMed ID: 17088978
[TBL] [Abstract][Full Text] [Related]
6. Combined ionizing radiation and sKDR gene delivery for treatment of prostate carcinomas.
Kaliberov SA; Kaliberova LN; Buchsbaum DJ
Gene Ther; 2005 Mar; 12(5):407-17. PubMed ID: 15616600
[TBL] [Abstract][Full Text] [Related]
7. Expression of the antiangiogenic factor 16K hPRL in human HCT116 colon cancer cells inhibits tumor growth in Rag1(-/-) mice.
Bentzien F; Struman I; Martini JF; Martial J; Weiner R
Cancer Res; 2001 Oct; 61(19):7356-62. PubMed ID: 11585777
[TBL] [Abstract][Full Text] [Related]
8. Tumor-suppressive activity of CD66a in prostate cancer.
Luo W; Tapolsky M; Earley K; Wood CG; Wilson DR; Logothetis CJ; Lin SH
Cancer Gene Ther; 1999; 6(4):313-21. PubMed ID: 10419049
[TBL] [Abstract][Full Text] [Related]
9. Adenovirus-mediated delivery of human IFNgamma gene inhibits prostate cancer growth.
Zhao P; Zhu YH; Wu JX; Liu RY; Zhu XY; Xiao X; Li HL; Huang BJ; Xie FJ; Chen JM; Ke ML; Huang W
Life Sci; 2007 Aug; 81(9):695-701. PubMed ID: 17714738
[TBL] [Abstract][Full Text] [Related]
10. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence.
Steiner MS; Zhang Y; Farooq F; Lerner J; Wang Y; Lu Y
Cancer Gene Ther; 2000 Mar; 7(3):360-72. PubMed ID: 10766342
[TBL] [Abstract][Full Text] [Related]
11. Carboxyl-terminal repressor domain of MBP-1 is sufficient for regression of prostate tumor growth in nude mice.
Ghosh AK; Steele R; Ray RB
Cancer Res; 2005 Feb; 65(3):718-21. PubMed ID: 15705866
[TBL] [Abstract][Full Text] [Related]
12. Sensitization of prostate cancer cell lines to 5-fluorocytosine induced by adenoviral vector carrying a CD transcription unit.
Yin L; Fu S; Wang X; Nanakorn T; Won J; Deisseroth A
Chin Med J (Engl); 2001 Sep; 114(9):972-5. PubMed ID: 11780394
[TBL] [Abstract][Full Text] [Related]
13. NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: immunogene therapy using a highly secretable form of interleukin-15 gene transfer.
Suzuki K; Nakazato H; Matsui H; Hasumi M; Shibata Y; Ito K; Fukabori Y; Kurokawa K; Yamanaka H
J Leukoc Biol; 2001 Apr; 69(4):531-7. PubMed ID: 11310838
[TBL] [Abstract][Full Text] [Related]
14. The application of an anti-angiogenic gene (thrombospondin-1) in the treatment of human prostate cancer xenografts.
Jin RJ; Kwak C; Lee SG; Lee CH; Soo CG; Park MS; Lee E; Lee SE
Cancer Gene Ther; 2000 Dec; 7(12):1537-42. PubMed ID: 11228532
[TBL] [Abstract][Full Text] [Related]
15. Cotargeting tumor and stroma in a novel chimeric tumor model involving the growth of both human prostate cancer and bone stromal cells.
Hsieh CL; Gardner TA; Miao L; Balian G; Chung LW
Cancer Gene Ther; 2004 Feb; 11(2):148-55. PubMed ID: 14695756
[TBL] [Abstract][Full Text] [Related]
16. Prostate-restricted replicative adenovirus expressing human endostatin-angiostatin fusion gene exhibiting dramatic antitumor efficacy.
Li X; Liu YH; Lee SJ; Gardner TA; Jeng MH; Kao C
Clin Cancer Res; 2008 Jan; 14(1):291-9. PubMed ID: 18172281
[TBL] [Abstract][Full Text] [Related]
17. Blockade of transforming growth factor-beta signaling suppresses progression of androgen-independent human prostate cancer in nude mice.
Zhang F; Lee J; Lu S; Pettaway CA; Dong Z
Clin Cancer Res; 2005 Jun; 11(12):4512-20. PubMed ID: 15958637
[TBL] [Abstract][Full Text] [Related]
18. Transcription-targeted gene therapy for androgen-independent prostate cancer.
Martiniello-Wilks R; Tsatralis T; Russell P; Brookes DE; Zandvliet D; Lockett LJ; Both GW; Molloy PL; Russell PJ
Cancer Gene Ther; 2002 May; 9(5):443-52. PubMed ID: 11961667
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of the glucocorticoid response during Ad5IL-12 adenovirus vector treatment enhances natural killer cell-mediated killing of MHC class I-negative LNCaP prostate tumors.
Raja Gabaglia C; Diaz de Durana Y; Graham FL; Gauldie J; Sercarz EE; Braciak TA
Cancer Res; 2007 Mar; 67(5):2290-7. PubMed ID: 17332360
[TBL] [Abstract][Full Text] [Related]
20. Recombinant adenovirus-p53 gene transfer and cell-specific growth suppression of human cervical cancer cells in vitro and in vivo.
Ahn WS; Bae SM; Lee KH; Lee JM; Namkoong SE; Chun HJ; Kim CK; Kim YW
Gynecol Oncol; 2004 Feb; 92(2):611-21. PubMed ID: 14766255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
